Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a9e9ce63eb0bbf3658453fb50a6d9b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
filingDate |
2020-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04b1753633e66d50ae778198a80f9755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_780bb038a7b186969b15dae604b0cc99 |
publicationDate |
2022-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20220024191-A |
titleOfInvention |
Anticancer drug combination therapy |
abstract |
The present invention describes an anti-cancer therapy comprising the use of a SOS1 inhibitor described herein in combination with a MEK inhibitor described herein. |
priorityDate |
2019-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |